Acquisition StrategyAlcon announces it plans to acquire Staar Surgical, which would complement Alcon’s existing refractive portfolio well, strengthening Alcon’s offering for individuals with more severe myopia.
FDA ApprovalFDA approval has been secured for TRYPTYR, the drug is indicated for both the signs and symptoms of dry eye disease, which is a significant milestone for ALC.
Product Launch And GrowthThe product launch cycle is expected to fuel appealing exit rates for 2026, enhancing growth prospects.